John Latham's Email & Phone

Previously he was Vice President of Gene Function and Target Validation for Celltech Group plc. In 1994 he joined Darwin Molecular, a first-generation gene-to-drug Biotechnology Company, as a founding director. His responsibilities included translating novel genes into therapeutic targets and ultimately providing a first-generation therapeutic agent. His efforts were centered in inflammation, autoimmune diseases, and osteoporosis, and provided important components to Celltech's therapeutic pipeline. The osteoporosis research led by Dr. Latham provided the underpinning for the Amgen/Celltech collaboration for the development of novel therapeutics to treat bone disorders. Prior to working at Darwin Molecular, he was one of the first scientists hired by Gilead Sciences and a member of a core group established to exploit novel oligonucleotide-based technologies. As a member of this team, he played a critical role in developing and implementing technology that enabled Gilead Sciences to establish itself as a leader in the field of random oligonucleotide selection biochemistry. Dr. Latham received his Ph.D. in Biochemistry from the Massachusetts Institute of Technology in the laboratory of Professor Christopher Walsh and conducted post-graduate research with Professor Thomas Cech at the University of Colorado, Boulder.